Andrea Schmitt

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4993724/publications.pdf

Version: 2024-02-01

222 papers	8,659 citations	36299 51 h-index	56717 83 g-index
235 all docs	235 docs citations	235 times ranked	11371 citing authors

#	Article	IF	Citations
1	Expression of Lineage Transcription Factors Identifies Differences in Transition States of Induced Human Oligodendrocyte Differentiation. Cells, 2022, 11, 241.	4.1	5
2	Sex-dependent effects of long-term clozapine or haloperidol medication on red blood cells and liver iron metabolism in Sprague Dawley rats as a model of metabolic syndrome. BMC Pharmacology & Toxicology, 2022, 23, 8.	2.4	4
3	Concept of the Munich/Augsburg Consortium Precision in Mental Health for the German Center of Mental Health. Frontiers in Psychiatry, 2022, 13, 815718.	2.6	2
4	Aerobic exercise in severe mental illness: requirements from the perspective of sports medicine. European Archives of Psychiatry and Clinical Neuroscience, 2022, 272, 643-677.	3.2	15
5	Failed regeneration and inflammation in schizophrenia: two sides of the same coin?. Journal of Neural Transmission, 2022, , 1.	2.8	1
6	Association between aerobic fitness and the functional connectome in patients with schizophrenia. European Archives of Psychiatry and Clinical Neuroscience, 2022, 272, 1253-1272.	3.2	4
7	An overview of the human brain myelin proteome and differences associated with schizophrenia. World Journal of Biological Psychiatry, 2021, 22, 271-287.	2.6	8
8	Aerobic endurance training to improve cognition and enhance recovery in schizophrenia: design and methodology of a multicenter randomized controlled trial. European Archives of Psychiatry and Clinical Neuroscience, 2021, 271, 315-324.	3.2	11
9	Association Between Physical Activity and Schizophrenia. JAMA Psychiatry, 2021, 78, 441.	11.0	14
10	Linking proteomic alterations in schizophrenia hippocampus to NMDAr hypofunction in human neurons and oligodendrocytes. European Archives of Psychiatry and Clinical Neuroscience, 2021, 271, 1579-1586.	3.2	5
11	Differential gene regulation in the anterior cingulate cortex and superior temporal cortex in schizophrenia: A molecular network approach. Schizophrenia Research, 2021, 232, 1-10.	2.0	4
12	Improvement in daily functioning after aerobic exercise training in schizophrenia is sustained after exercise cessation. European Archives of Psychiatry and Clinical Neuroscience, 2021, 271, 1201-1203.	3.2	10
13	Exercise as a model to identify microRNAs linked to human cognition: a role for microRNA-409 and microRNA-501. Translational Psychiatry, 2021, 11, 514.	4.8	10
14	Medication Adherence in a Cross-Diagnostic Sample of Patients From the Affective-to-Psychotic Spectrum: Results From the PsyCourse Study. Frontiers in Psychiatry, 2021, 12, 713060.	2.6	8
15	The efficacy and safety of cariprazine in the early and late stage of schizophrenia: a post hoc analysis of three randomized, placebo-controlled trials. CNS Spectrums, 2021, , 1-8.	1.2	0
16	Effects of Three Months of Aerobic Endurance Training on Motor Cortical Excitability in Schizophrenia Patients and Healthy Subjects. Neuropsychobiology, 2020, 79, 100-107.	1.9	3
17	Association between altered hippocampal oligodendrocyte number and neuronal circuit structures in schizophrenia: a postmortem analysis. European Archives of Psychiatry and Clinical Neuroscience, 2020, 270, 413-424.	3.2	9
18	The impact of endurance training and table soccer on brain metabolites in schizophrenia. Brain Imaging and Behavior, 2020, 14, 515-526.	2.1	6

#	Article	IF	Citations
19	Effect of aerobic exercise combined with cognitive remediation on cortical thickness and prediction of social adaptation in patients with schizophrenia. Schizophrenia Research, 2020, 216, 397-407.	2.0	21
20	Modeling Obstetric Complications in Schizophrenia. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2020, 5, 1070-1071.	1.5	0
21	Viewing an alpine environment positively affects emotional analytics in patients with somatoform, depressive and anxiety disorders as well as in healthy controls. BMC Psychiatry, 2020, 20, 385.	2.6	3
22	Impact of the metabolic syndrome on severe mental disorders. European Archives of Psychiatry and Clinical Neuroscience, 2020, 270, 499-500.	3.2	2
23	Sexâ€dependent alterations of dopamine receptor and glucose transporter density in rat hypothalamus under longâ€term clozapine and haloperidol medication. Brain and Behavior, 2020, 10, e01694.	2.2	10
24	Affected neural networks as basis of disturbed motor function in schizophrenia. European Archives of Psychiatry and Clinical Neuroscience, 2020, 270, 279-280.	3.2	0
25	Effect of aerobic exercise on cortical thickness in patients with schizophreniaâ€"A dataset. Data in Brief, 2020, 30, 105517.	1.0	2
26	The effect of physical activity in an alpine environment on quality of life is mediated by resilience in patients with psychosomatic disorders and healthy controls. European Archives of Psychiatry and Clinical Neuroscience, 2019, 269, 543-553.	3.2	18
27	The need to develop personalized interventions to improve cognition in schizophrenia. World Psychiatry, 2019, 18, 170-170.	10.4	21
28	Aerobic exercise in mental disorders: from basic mechanisms to treatment recommendations. European Archives of Psychiatry and Clinical Neuroscience, 2019, 269, 483-484.	3.2	7
29	Polygenic burden associated to oligodendrocyte precursor cells and radial glia influences the hippocampal volume changes induced by aerobic exercise in schizophrenia patients. Translational Psychiatry, 2019, 9, 284.	4.8	14
30	Quantitative Subcellular Proteomics of the Orbitofrontal Cortex of Schizophrenia Patients. Journal of Proteome Research, 2019, 18, 4240-4253.	3.7	21
31	Dysregulation of a specific immune-related network of genes biologically defines a subset of schizophrenia. Translational Psychiatry, 2019, 9, 156.	4.8	24
32	Neurobiological effects of aerobic exercise, with a focus on patients with schizophrenia. European Archives of Psychiatry and Clinical Neuroscience, 2019, 269, 499-515.	3.2	35
33	A new role for oligodendrocytes and myelination in schizophrenia and affective disorders?. European Archives of Psychiatry and Clinical Neuroscience, 2019, 269, 371-372.	3.2	29
34	Childhood Trauma in Schizophrenia: Current Findings and Research Perspectives. Frontiers in Neuroscience, 2019, 13, 274.	2.8	99
35	The Influence of Continuous Exercising on Chronotropic Incompetence in Multi-Episode Schizophrenia. Frontiers in Psychiatry, 2019, 10, 90.	2.6	7
36	Depression in Somatic Disorders: Is There a Beneficial Effect of Exercise?. Frontiers in Psychiatry, 2019, 10, 141.	2.6	18

#	Article	IF	Citations
37	Oligodendrocytes as A New Therapeutic Target in Schizophrenia: From Histopathological Findings to Neuron-Oligodendrocyte Interaction. Cells, 2019, 8, 1496.	4.1	49
38	T1-MPRAGE and T2-FLAIR segmentation of cortical and subcortical brain regionsâ€”an MRI evaluation study. Neuroradiology, 2019, 61, 129-136.	2.2	7
39	Stigma experiences and perceived stigma in patients with first-episode schizophrenia in the course of 1Ayear after their first in-patient treatment. European Archives of Psychiatry and Clinical Neuroscience, 2019, 269, 459-468.	3.2	19
40	Nonpharmacological treatment of dyscognition in schizophrenia: effects â€¨of aerobic exercise. Dialogues in Clinical Neuroscience, 2019, 21, 261-269.	3.7	8
41	Verbesserung der GehirnplastizitÃt bei der Schizophrenie: MÃ¶glichkeit therapeutischer Verbesserungen?. , 2019, , 83-96.		0
42	Brain changes in psychosis. , 2019, , 45-56.		0
43	Improving brain plasticity in schizophrenia: possibility for therapeutic advancements?. , 2019, , 85-96.		0
44	Effects of haloperidol and clozapine on synapse-related gene expression in specific brain regions of male rats. European Archives of Psychiatry and Clinical Neuroscience, 2018, 268, 555-563.	3.2	9
45	A systematic review of trials investigating strength training in schizophrenia spectrum disorders. Schizophrenia Research, 2018, 192, 64-68.	2.0	21
46	11.3 CLINICAL AND NEUROBIOLOGICAL EFFECTS OF A CONTINUOUS AEROBIC ENDURANCE TRAINING IN MULTI-EPISODE SCHIZOPHRENIA PATIENTS. Schizophrenia Bulletin, 2018, 44, S17-S18.	4.3	0
47	Studying and modulating schizophrenia-associated dysfunctions of oligodendrocytes with patient-specific cell systems. NPJ Schizophrenia, 2018, 4, 23.	3.6	31
48	Effects of Aerobic Exercise on Metabolic Syndrome, Cardiorespiratory Fitness, and Symptoms in Schizophrenia Include Decreased Mortality. Frontiers in Psychiatry, 2018, 9, 690.	2.6	57
49	EPA guidance on physical activity as a treatment for severe mental illness: a meta-review of the evidence and Position Statement from the European Psychiatric Association (EPA), supported by the International Organization of Physical Therapists in Mental Health (IOPTMH). European Psychiatry, 2018, 54, 124-144.	0.2	377
50	Impaired recovery in affective disorders and schizophrenia: sharing a common pathophysiology?. European Archives of Psychiatry and Clinical Neuroscience, 2018, 268, 739-740.	3.2	1
51	Forty years of structural brain imaging in mental disorders: is it clinically useful or not?. Dialogues in Clinical Neuroscience, 2018, 20, 179-186.	3.7	31
52	Peptidomic analysis of the anterior temporal lobe and corpus callosum from schizophrenia patients. Journal of Proteomics, 2017, 151, 97-105.	2.4	22
53	Aerobic exercise in major psychiatric disorders: promises and challenges. European Archives of Psychiatry and Clinical Neuroscience, 2017, 267, 93-94.	3.2	4
54	Aerobic exercise and its effects on cognition in schizophrenia. Current Opinion in Psychiatry, 2017, 30, 171-175.	6.3	41

#	Article	IF	Citations
55	HDAC1 links early life stress to schizophrenia-like phenotypes. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E4686-E4694.	7.1	75
56	Synaptosomal Proteome of the Orbitofrontal Cortex from Schizophrenia Patients Using Quantitative Label-Free and iTRAQ-Based Shotgun Proteomics. Journal of Proteome Research, 2017, 16, 4481-4494.	3.7	44
57	Formin 2 links neuropsychiatric phenotypes at young age to an increased risk for dementia. EMBO Journal, 2017, 36, 2815-2828.	7.8	45
58	The Nuclear Proteome of White and Gray Matter from Schizophrenia Postmortem Brains. Molecular Neuropsychiatry, 2017, 3, 37-52.	2.9	32
59	On the search of new treatment strategies in patients with affective disorders. European Archives of Psychiatry and Clinical Neuroscience, 2017, 267, 709-710.	3.2	0
60	Polygenic risk has an impact on the structural plasticity of hippocampal subfields during aerobic exercise combined with cognitive remediation in multi-episode schizophrenia. Translational Psychiatry, 2017, 7, e1159-e1159.	4.8	56
61	Consensus paper of the WFSBP Task Force on Biological Markers: Criteria for biomarkers and endophenotypes of schizophrenia, part III: Molecular mechanisms. World Journal of Biological Psychiatry, 2017, 18, 330-356.	2.6	33
62	Aerobic exercise for people with schizophrenic psychosis. , 2016, , 66-78.		0
63	Oligodendrocyte and Interneuron Density in Hippocampal Subfields in Schizophrenia and Association of Oligodendrocyte Number with Cognitive Deficits. Frontiers in Cellular Neuroscience, 2016, 10, 78.	3.7	37
64	News from the graveyard: Neuropathological research on schizophrenia is alive and productive. Schizophrenia Research, 2016, 177, 1-2.	2.0	2
65	Neurobiological background of borderline personality disorder, PTSD and ADHD. European Archives of Psychiatry and Clinical Neuroscience, 2016, 266, 289-290.	3.2	0
66	Endurance training in patients with schizophrenia and healthy controls: differences and similarities. European Archives of Psychiatry and Clinical Neuroscience, 2016, 266, 461-473.	3.2	22
67	Reduced oxytocin receptor gene expression and binding sites in different brain regions in schizophrenia: A post-mortem study. Schizophrenia Research, 2016, 177, 59-66.	2.0	58
68	Perspectives of neurobiological research in schizophrenia. Neurology Psychiatry and Brain Research, 2016, 22, 63-68.	2.0	2
69	Differential proteome and phosphoproteome may impact cell signaling in the corpus callosum of schizophrenia patients. Schizophrenia Research, 2016, 177, 70-77.	2.0	22
70	Neuroscience-based nomenclature (jNbN) to replace traditional terminology of psychotropic medications. European Archives of Psychiatry and Clinical Neuroscience, 2016, 266, 385-386.	3.2	7
71	Decreased Oligodendrocyte and Neuron Number in Anterior Hippocampal Areas and the Entire Hippocampus in Schizophrenia: A Stereological Postmortem Study. Schizophrenia Bulletin, 2016, 42, S4-S12.	4.3	68
72	Stepping up: the just released new impact factor 2015. European Archives of Psychiatry and Clinical Neuroscience, 2016, 266, 475-476.	3.2	1

#	Article	IF	Citations
73	Consensus paper of the WFSBP Task Force on Biological Markers: Criteria for biomarkers and endophenotypes of schizophrenia part II: Cognition, neuroimaging and genetics. World Journal of Biological Psychiatry, 2016, 17, 406-428.	2.6	30
74	Morphological and functional alterations in patients with schizophrenia spectrum disorders. European Archives of Psychiatry and Clinical Neuroscience, 2016, 266, 1-2.	3.2	2
75	Effects of endurance training on brain structures in chronic schizophrenia patients and healthy controls. Schizophrenia Research, 2016, 173, 182-191.	2.0	64
76	Predictors for symptom re-exacerbation after targeted stepwise drug discontinuation in first-episode schizophrenia. Schizophrenia Research, 2016, 170, 168-176.	2.0	34
77	GABAergic system impairment in the hippocampus and superior temporal gyrus of patients with paranoid schizophrenia: A post-mortem study. Schizophrenia Research, 2016, 177, 10-17.	2.0	27
78	Pioneering ambient mass spectrometry imaging in psychiatry: Potential for new insights into schizophrenia. Schizophrenia Research, 2016, 177, 67-69.	2.0	11
79	Disturbed macro-connectivity in schizophrenia linked to oligodendrocyte dysfunction: from structural findings to molecules. NPJ Schizophrenia, 2015, 1, 15034.	3.6	64
80	Unravelling basic mechanisms in addiction and neuropsychiatric disorders. European Archives of Psychiatry and Clinical Neuroscience, 2015, 265, 633-635.	3.2	0
81	MK-801 treatment affects glycolysis in oligodendrocytes more than in astrocytes and neuronal cells: insights for schizophrenia. Frontiers in Cellular Neuroscience, 2015, 09, 180.	3.7	35
82	BDNF-Val66Met-Polymorphism Impact on Cortical Plasticity in Schizophrenia Patients: A Proof-of-Concept Study. International Journal of Neuropsychopharmacology, 2015, 18, .	2.1	25
83	Stereological investigation of the posterior hippocampus in affective disorders. Journal of Neural Transmission, 2015, 122, 1019-1033.	2.8	25
84	Erythropoietin as an Innovative Add-on Therapy for Depression. Biological Psychiatry, 2015, 78, 222-223.	1.3	2
85	Psychiatristsâ€™ self-stigma, the DGPPN guideline for psychosocial interventions, and contemporary treatment strategies. European Archives of Psychiatry and Clinical Neuroscience, 2015, 265, 171-172.	3.2	9
86	Schizophrenia spectrum and related neuropathology. European Archives of Psychiatry and Clinical Neuroscience, 2015, 265, 85-86.	3.2	2
87	Consensus paper of the WFSBP Task Force on Biological Markers: Criteria for biomarkers and endophenotypes of schizophrenia part I: Neurophysiology. World Journal of Biological Psychiatry, 2015, 16, 280-290.	2.6	37
88	Family load impacts orbitofrontal volume in first-episode schizophrenia. Psychiatry Research - Neuroimaging, 2015, 232, 130-133.	1.8	1
89	Classification and neurobiological concepts of mania, bipolar disorder and major depression. European Archives of Psychiatry and Clinical Neuroscience, 2015, 265, 271-272.	3.2	2
90	Pathways to personalized treatment strategies for depressive disorders. European Archives of Psychiatry and Clinical Neuroscience, 2015, 265, 1-3.	3.2	1

#	Article	IF	Citations
91	Kraepelin revisited: schizophrenia from degeneration to failed regeneration. Molecular Psychiatry, 2015, 20, 671-676.	7.9	83
92	Effects of Endurance Training Combined With Cognitive Remediation on Everyday Functioning, Symptoms, and Cognition in Multiepisode Schizophrenia Patients. Schizophrenia Bulletin, 2015, 41, 847-858.	4.3	83
93	Negative symptoms and therapy strategies in schizophrenia. European Archives of Psychiatry and Clinical Neuroscience, 2015, 265, 541-542.	3.2	3
94	Genetic and environmental risk factors in neurodevelopmental disorders. European Archives of Psychiatry and Clinical Neuroscience, 2015, 265, 445-447.	3.2	1
95	DGPPN guideline on anxiety disorders and cognitive dysfunction in the elderly or patients with multiple sclerosis. European Archives of Psychiatry and Clinical Neuroscience, 2015, 265, 361-362.	3.2	0
96	Proteomics of the corpus callosum unravel pivotal players in the dysfunction of cell signaling, structure, and myelination in schizophrenia brains. European Archives of Psychiatry and Clinical Neuroscience, 2015, 265, 601-612.	3.2	70
97	Common mechanisms in neurodegeneration and neuroinflammation: a BrainNet Europe gene expression microarray study. Journal of Neural Transmission, 2015, 122, 1055-1068.	2.8	126
98	The impact of environmental factors in severe psychiatric disorders. Frontiers in Neuroscience, 2014, 8, 19.	2.8	242
99	Selected issues of the DGPPN Congress in 2013. European Archives of Psychiatry and Clinical Neuroscience, 2014, 264, 1-2.	3.2	0
100	Proteomic Characterization of the Brain and Cerebrospinal Fluid of Schizophrenia Patients. Advances in Biological Psychiatry, 2014, , 1-1.	0.2	0
101	Antipsychotic treatment modulates glutamate transport and NMDA receptor expression. European Archives of Psychiatry and Clinical Neuroscience, 2014, 264, 67-82.	3.2	20
102	New aspects of cognition domains and psychopathological measures in psychiatry. European Archives of Psychiatry and Clinical Neuroscience, 2014, 264, 647-649.	3.2	0
103	CACNA1C genotype explains interindividual differences in amygdala volume among patients with schizophrenia. European Archives of Psychiatry and Clinical Neuroscience, 2014, 264, 93-102.	3.2	50
104	The new risk variant CACNA1C and brain circuits in schizophrenia. European Archives of Psychiatry and Clinical Neuroscience, 2014, 264, 91-92.	3.2	2
105	S100B is downregulated in the nuclear proteome of schizophrenia corpus callosum. European Archives of Psychiatry and Clinical Neuroscience, 2014, 264, 311-316.	3.2	18
106	Effects of aerobic exercise on cognitive performance and individual psychopathology in depressive and schizophrenia patients. European Archives of Psychiatry and Clinical Neuroscience, 2014, 264, 589-604.	3.2	133
107	Comorbidity, stigma and emotional perception in psychiatric disorders. European Archives of Psychiatry and Clinical Neuroscience, 2014, 264, 1-2.	3.2	2
108	Ten years of proteomics in multiple sclerosis. Proteomics, 2014, 14, 467-480.	2.2	31

#	Article	IF	Citations
109	Rates and predictors of remission in first-episode schizophrenia within 1 year of antipsychotic maintenance treatment. Results of a randomized controlled trial within the German Research Network on Schizophrenia. Schizophrenia Research, 2014, 152, 478-486.	2.0	33
110	Deciphering the Human Brain Proteome: Characterization of the Anterior Temporal Lobe and Corpus Callosum As Part of the Chromosome 15-centric Human Proteome Project. Journal of Proteome Research, 2014, 13, 147-157.	3.7	16
111	Connectivity and cognition in neuropsychiatric disorders with special emphasis on Alzheimerâ€™s disease and Chorea Huntington. European Archives of Psychiatry and Clinical Neuroscience, 2014, 264, 465-466.	3.2	0
112	Reward, memory and prediction of treatment response in affective disorders. European Archives of Psychiatry and Clinical Neuroscience, 2014, 264, 185-186.	3.2	0
113	The neuropathology of schizophrenia: new insights from postmortem studies. European Archives of Psychiatry and Clinical Neuroscience, 2014, 264, 269-270.	3.2	3
114	Historical aspects of Mozartâ€™s mental health and diagnostic insights of ADHD and personality disorders. European Archives of Psychiatry and Clinical Neuroscience, 2014, 264, 363-365.	3.2	2
115	Suicide ideation, stability of symptoms and effects of aerobic exercise in major depression. European Archives of Psychiatry and Clinical Neuroscience, 2014, 264, 555-556.	3.2	2
116	The effects of physical exercise in schizophrenia and affective disorders. European Archives of Psychiatry and Clinical Neuroscience, 2013, 263, 451-467.	3.2	90
117	Impact of lifestyle in severe psychiatric disorders and brain morphology. European Archives of Psychiatry and Clinical Neuroscience, 2013, 263, 449-450.	3.2	1
118	Pattern and volume of the anterior cingulate cortex in chronic posttraumatic stress disorder (PTSD). European Archives of Psychiatry and Clinical Neuroscience, 2013, 263, 585-592.	3.2	7
119	The glutamate system as a therapeutic target and impact of genes on suicidality. European Archives of Psychiatry and Clinical Neuroscience, 2013, 263, 365-366.	3.2	0
120	Innovative potential treatment strategies for schizophrenia and biomarkers for Alzheimerâ€™s disease. European Archives of Psychiatry and Clinical Neuroscience, 2013, 263, 271-272.	3.2	0
121	Aripiprazole differentially regulates the expression of Gad67 and Î³-aminobutyric acid transporters in rat brain. European Archives of Psychiatry and Clinical Neuroscience, 2013, 263, 285-297.	3.2	14
122	Risk genes, metabolic syndrome and eye tracking deficits in psychiatric diseases. European Archives of Psychiatry and Clinical Neuroscience, 2013, 263, 177-179.	3.2	1
123	Differential diagnosis of major depression and bipolar disorder. European Archives of Psychiatry and Clinical Neuroscience, 2013, 263, 83-84.	3.2	2
124	The effect of aerobic exercise on cortical architecture in patients with chronic schizophrenia: a randomized controlled MRI study. European Archives of Psychiatry and Clinical Neuroscience, 2013, 263, 469-473.	3.2	58
125	Proteomic Similarities Between Heterozygous Reeler Mice and Schizophrenia. Biological Psychiatry, 2013, 74, e5-e10.	1.3	11
126	Selected topics of the DGPPN Congress 2012. European Archives of Psychiatry and Clinical Neuroscience, 2013, 263, 121-122.	3.2	0

#	Article	IF	Citations
127	Effects of cannabis and familial loading on subcortical brain volumes in first-episode schizophrenia. European Archives of Psychiatry and Clinical Neuroscience, 2013, 263, 155-168.	3.2	24
128	Brain imaging to be on track for improving diagnosis and pathophysiological insights in neuropsychiatric diseases. European Archives of Psychiatry and Clinical Neuroscience, 2013, 263, 537-538.	3.2	0
129	Therapeutic targets in major psychiatric disorders revisited. European Archives of Psychiatry and Clinical Neuroscience, 2013, 263, 619-620.	3.2	3
130	Gene expression of glutamate transporters SLC1A1, SLC1A3 and SLC1A6 in the cerebellar subregions of elderly schizophrenia patients and effects of antipsychotic treatment. World Journal of Biological Psychiatry, 2013, 14, 490-499.	2.6	15
131	Cannabis abuse and brain morphology in schizophrenia: a review of the available evidence. European Archives of Psychiatry and Clinical Neuroscience, 2013, 263, 3-13.	3.2	40
132	Schizophrenia: brain morphology and treatment aspects. European Archives of Psychiatry and Clinical Neuroscience, 2013, 263, 1-2.	3.2	1
133	Increased cell proliferation in the rat anterior cingulate cortex following neonatal hypoxia: relevance to schizophrenia. Journal of Neural Transmission, 2013, 120, 187-195.	2.8	19
134	Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders. European Archives of Psychiatry and Clinical Neuroscience, 2013, 263, 367-377.	3.2	177
135	The human oligodendrocyte proteome. Proteomics, 2013, 13, 3548-3553.	2.2	24
136	Differential Expression of Exosomal microRNAs in Prefrontal Cortices of Schizophrenia and Bipolar Disorder Patients. PLoS ONE, 2013, 8, e48814.	2.5	205
137	Estudos transcriptÃ´micos no contexto da conectividade perturbada em esquizofrenia. Revista De Psiquiatria Clinica, 2013, 40, 10-15.	0.6	3
138	Akathisia and Suicidal Ideation in First-Episode Schizophrenia. Journal of Clinical Psychopharmacology, 2012, 32, 694-698.	1.4	29
139	Depressive symptoms and their association with acute treatment outcome in first-episode schizophrenia patients: Comparing treatment with risperidone and haloperidol. World Journal of Biological Psychiatry, 2012, 13, 30-38.	2.6	23
140	Selection of novel reference genes for use in the human central nervous system: a BrainNet Europe Study. Acta Neuropathologica, 2012, 124, 893-903.	7.7	110
141	Abnormal bihemispheric responses in schizophrenia patients following cathodal transcranial direct stimulation. European Archives of Psychiatry and Clinical Neuroscience, 2012, 262, 415-423.	3.2	30
142	Structural synaptic elements are differentially regulated in superior temporal cortex of schizophrenia patients. European Archives of Psychiatry and Clinical Neuroscience, 2012, 262, 565-577.	3.2	31
143	Schizophrenia: from risk genes to outcome and comorbidity. European Archives of Psychiatry and Clinical Neuroscience, 2012, 262, 547-548.	3.2	1
144	On our own behalf: a new editorial board and focus of EAPCN. European Archives of Psychiatry and Clinical Neuroscience, 2012, 262, 545-546.	3.2	0

#	Article	IF	Citations
145	Post-mortem findings in mood disorders, nightmares and therapeutic approaches of psychiatric diseases. European Archives of Psychiatry and Clinical Neuroscience, 2012, 262, 635-636.	3.2	0
146	Different distribution patterns of lymphocytes and microglia in the hippocampus of patients with residual versus paranoid schizophrenia: Further evidence for disease course-related immune alterations?. Brain, Behavior, and Immunity, 2012, 26, 1273-1279.	4.1	165
147	Selected issues of the DGPPN Congress in 2011. European Archives of Psychiatry and Clinical Neuroscience, 2012, 262, 49-50.	3.2	0
148	Decreased Reelin Expression in the Left Prefrontal Cortex (BA9) in Chronic Schizophrenia Patients. Neuropsychobiology, 2012, 66, 57-62.	1.9	36
149	Increased Density of Prohibitin-Immunoreactive Oligodendrocytes in the Dorsolateral Prefrontal White Matter of Subjects with Schizophrenia Suggests Extraneuronal Roles for the Protein in the Disease. NeuroMolecular Medicine, 2012, 14, 270-280.	3.4	25
150	Association of the brain-derived neurotrophic factor val66met polymorphism with magnetic resonance spectroscopic markers in the human hippocampus: in vivo evidence for effects on the glutamate system. European Archives of Psychiatry and Clinical Neuroscience, 2012, 262, 23-31.	3.2	41
151	Differential expression of HINT1 in schizophrenia brain tissue. European Archives of Psychiatry and Clinical Neuroscience, 2012, 262, 167-172.	3.2	24
152	Reduction of gyrification index in the cerebellar vermis in schizophrenia: A post-mortem study. World Journal of Biological Psychiatry, 2011, 12, 99-103.	2.6	15
153	Regulation of immune-modulatory genes in left superior temporal cortex of schizophrenia patients: a genome-wide microarray study. World Journal of Biological Psychiatry, 2011, 12, 201-215.	2.6	60
154	The Hypoxic Rat Model for Obstetric Complications in Schizophrenia. Neuromethods, 2011, , 93-111.	0.3	0
155	Predictors of response and remission in the acute treatment of first-episode schizophrenia patients â€" Is it all about early response?. European Neuropsychopharmacology, 2011, 21, 370-378.	0.7	46
156	The role of the cerebellum in schizophrenia: from cognition to molecular pathways. Clinics, 2011, 66, 71-77.	1.5	91
157	New lexicon and criteria for the diagnosis of Alzheimer's disease. Lancet Neurology, The, 2011, 10, 298-299.	10.2	26
158	Methyl- and acetyltransferases are stable epigenetic markers postmortem. Cell and Tissue Banking, 2011, 12, 289-297.	1.1	12
159	Schizophrenia as a disorder of disconnectivity. European Archives of Psychiatry and Clinical Neuroscience, 2011, 261, 150-154.	3.2	197
160	Effects of chronic oral treatment with aripiprazole on the expression of NMDA receptor subunits and binding sites in rat brain. Psychopharmacology, 2011, 217, 127-142.	3.1	20
161	Perinatal asphyxia: current status and approaches towards neuroprotective strategies, with focus on sentinel proteins. Neurotoxicity Research, 2011, 19, 603-627.	2.7	44
162	microRNA-34c is a novel target to treat dementias. EMBO Journal, 2011, 30, 4299-4308.	7.8	302

#	Article	IF	Citations
163	Relapse Prevention in First-Episode Schizophreniaâ€"Maintenance vs Intermittent Drug Treatment With Prodrome-Based Early Intervention. Journal of Clinical Psychiatry, 2011, 72, 205-218.	2.2	79
164	Gene expression of NMDA receptor subunits in the cerebellum of elderly patients with schizophrenia. European Archives of Psychiatry and Clinical Neuroscience, 2010, 260, 101-111.	3.2	41
165	Sex-specific proteome differences in the anterior cingulate cortex of schizophrenia. Journal of Psychiatric Research, 2010, 44, 989-991.	3.1	72
166	Proteome analysis of the thalamus and cerebrospinal fluid reveals glycolysis dysfunction and potential biomarkers candidates for schizophrenia. Journal of Psychiatric Research, 2010, 44, 1176-1189.	3.1	158
167	Sex-dependent behavioral effects and morphological changes in the hippocampus after prenatal invasive interventions in rats: implications for animal models of schizophrenia. Clinics, 2010, 65, 209-219.	1.5	12
168	The impact of antipsychotic drugs on food intake and body weight and on leptin levels in blood and hypothalamic ob-r leptin receptor expression in wistar rats. Clinics, 2010, 65, 885-894.	1.5	17
169	Thalamic nuclear abnormalities as a contributory factor in sudden cardiac deaths among patients with schizophrenia. Clinics, 2010, 65, 539-546.	1.5	6
170	Gene expression of neuregulin-1 isoforms in different brain regions of elderly schizophrenia patients. World Journal of Biological Psychiatry, 2010, 11, 243-250.	2.6	40
171	Reduced density of ADAM 12-immunoreactive oligodendrocytes in the anterior cingulate white matter of patients with schizophrenia. World Journal of Biological Psychiatry, 2010, 11, 556-566.	2.6	36
172	Different apolipoprotein E, apolipoprotein A1 and prostaglandin-H2 D-isomerase levels in cerebrospinal fluid of schizophrenia patients and healthy controls. World Journal of Biological Psychiatry, 2010, 11, 719-728.	2.6	47
173	Proteome analysis of schizophrenia brain tissue. World Journal of Biological Psychiatry, 2010, 11, 110-120.	2.6	82
174	The Neuropathology of Schizophrenia: Central Role for the Hippocampus?. , 2010, , 149-165.		3
175	DisfunÃ§Ã£o prÃ©-frontoparietal durante o processamento de informaÃ§Ã£o visuoauditiva em pacientes idosos com esquizofrenia crÃ´nica e efeitos da medicaÃ§Ã£o. Revista De Psiquiatria Clinica, 2009, 36, 89-96.	0.6	6
176	Proteomic analysis of dorsolateral prefrontal cortex indicates the involvement of cytoskeleton, oligodendrocyte, energy metabolism and new potential markers in schizophrenia. Journal of Psychiatric Research, 2009, 43, 978-986.	3.1	165
177	Association between myelin basic protein expression and left entorhinal cortex pre-alpha cell layer disorganization in schizophrenia. Brain Research, 2009, 1301, 126-134.	2.2	30
178	Shotgun mass spectrometry analysis of the human thalamus proteome. Journal of Separation Science, 2009, 32, 1231-1236.	2.5	21
179	Alterations in oligodendrocyte proteins, calcium homeostasis and new potential markers in schizophrenia anterior temporal lobe are revealed by shotgun proteome analysis. Journal of Neural Transmission, 2009, 116, 275-289.	2.8	137
180	Increased d-amino acid oxidase expression in the bilateral hippocampal CA4 of schizophrenic patients: a post-mortem study. Journal of Neural Transmission, 2009, 116, 1657-1665.	2.8	31

#	Article	IF	Citations
181	Stereologic investigation of the posterior part of the hippocampus in schizophrenia. Acta Neuropathologica, 2009, 117, 395-407.	7.7	146
182	Neuregulin 1 ICE-single nucleotide polymorphism in first episode schizophrenia correlates with cerebral activation in fronto-temporal areas. European Archives of Psychiatry and Clinical Neuroscience, 2009, 259, 72-79.	3.2	29
183	Prefrontal cortex shotgun proteome analysis reveals altered calcium homeostasis and immune system imbalance in schizophrenia. European Archives of Psychiatry and Clinical Neuroscience, 2009, 259, 151-163.	3.2	180
184	Internal capsule size associated with outcome in first-episode schizophrenia. European Archives of Psychiatry and Clinical Neuroscience, 2009, 259, 278-283.	3.2	34
185	Proteome analysis of schizophrenia patients Wernicke's area reveals an energy metabolism dysregulation. BMC Psychiatry, 2009, 9, 17.	2.6	133
186	pH measurement as quality control on human post mortem brain tissue: a study of the BrainNet Europe consortium. Neuropathology and Applied Neurobiology, 2009, 35, 329-337.	3.2	93
187	Tryptophan is a marker of human postmortem brain tissue quality. Journal of Neurochemistry, 2009, 110, 1400-1408.	3.9	13
188	Differential expression of glutamate transporter genes after chronic oral treatment with aripiprazole in rats. Neurochemistry International, 2009, 55, 619-628.	3.8	29
189	Schizophrenia: From the brain to peripheral markers. A consensus paper of the WFSBP task force on biological markers. World Journal of Biological Psychiatry, 2009, 10, 127-155.	2.6	64
190	Does the degree of smoking effect the severity of tardive dyskinesia? A longitudinal clinical trial. European Psychiatry, 2009, 24, 33-40.	0.2	26
191	Management of a twenty-first century brain bank: experience in the BrainNet Europe consortium. Acta Neuropathologica, 2008, 115, 497-507.	7.7	101
192	Impact of neuregulin-1 on the pathophysiology of schizophrenia in human post-mortem studies. European Archives of Psychiatry and Clinical Neuroscience, 2008, 258, 35-39.	3.2	20
193	Proteome analysis of human dorsolateral prefrontal cortex using shotgun mass spectrometry. Journal of Separation Science, 2008, 31, 3122-3126.	2.5	13
194	The LARK/RBM4a protein is highly expressed in cerebellum as compared to cerebrum. Neuroscience Letters, 2008, 444, 11-15.	2.1	5
195	Behavioural Alterations in Rats Following Neonatal Hypoxia and Effects of Clozapine: Implications for Schizophrenia. Pharmacopsychiatry, 2008, 41, 138-145.	3.3	28
196	Is Brain Banking of Psychiatric Cases Valuable for Neurobiological Research?. Clinics, 2008, 63, 255-266.	1.5	20
197	Neural correlates of working memory dysfunction in first-episode schizophrenia patients: An fMRI multi-center study. Schizophrenia Research, 2007, 89, 198-210.	2.0	148
198	Differential gene expression in peripheral blood of patients suffering from post-traumatic stress disorder. Molecular Psychiatry, 2007, 12, 116-118.	7.9	109

#	Article	IF	Citations
199	Effects of Formalin Fixation, Paraffin Embedding, and Time of Storage on DNA Preservation in Brain Tissue: A BrainNet Europe Study. Brain Pathology, 2007, 17, 297-303.	4.1	127
200	Altered NMDA receptor expression and behavior following postnatal hypoxia: potential relevance to schizophrenia. Journal of Neural Transmission, 2007, 114, 239-248.	2.8	22
201	How a neuropsychiatric brain bank should be run: a consensus paper of Brainnet Europe II. Journal of Neural Transmission, 2007, 114, 527-537.	2.8	49
202	Maintenance Treatment With Risperidone or Low-Dose Haloperidol in First-Episode Schizophrenia. Journal of Clinical Psychiatry, 2007, 68, 1763-1774.	2.2	76
203	D2 Antidopaminergic Modulation of Frontal Lobe Function in Healthy Human Subjects. Biological Psychiatry, 2006, 60, 1196-1205.	1.3	37
204	Disturbance in the neural circuitry underlying positive emotional processing in postâ€“traumatic stress disorder (PTSD). European Archives of Psychiatry and Clinical Neuroscience, 2006, 256, 112-114.	3.2	55
205	Hippocampal volume in chronic posttraumatic stress disorder (PTSD): MRI study using two different evaluation methods. Journal of Affective Disorders, 2006, 94, 121-126.	4.1	84
206	Protective Drugs in Acute Large-Dose Exposure to Organophosphates: A Comparison of Metoclopramide and Tiapride with Pralidoxime in Rats. Anesthesia and Analgesia, 2005, 100, 382-386.	2.2	28
207	vaccine development: Facing the challenge. International Journal of Medical Microbiology, 2005, 295, 343-353.	3.6	38
208	Increased serum S100B in elderly, chronic schizophrenic patients: Negative correlation with deficit symptoms. Schizophrenia Research, 2005, 80, 305-313.	2.0	68
209	Increased serum interleukin-I? and interleukin-6 in elderly, chronic schizophrenic patients on stable antipsychotic medication. Neuropsychiatric Disease and Treatment, 2005, 1, 171-177.	2.2	59
210	Differential Effects of Long-Term Treatment with Clozapine or Haloperidol on GABA Transporter Expression. Pharmacopsychiatry, 2004, 37, 171-174.	3.3	74
211	Ethanol Induces Expression of the Glutamate Transporters EAAT1 and EAAT2 in Organotypic Cortical Slice Cultures. Alcoholism: Clinical and Experimental Research, 2004, 28, 1752-1757.	2.4	22
212	Hippocampal volume and cell proliferation after acute and chronic clozapine or haloperidol treatment. Journal of Neural Transmission, 2004, 111, 91-100.	2.8	52
213	Differential effects of long-term treatment with clozapine or haloperidol on GABAA receptor binding and GAD67 expression. Schizophrenia Research, 2004, 66, 151-157.	2.0	57
214	Altered thalamic membrane phospholipids in schizophrenia: a postmortem study. Biological Psychiatry, 2004, 56, 41-45.	1.3	111
215	Glycerophosphocholine is elevated in cerebrospinal fluid of Alzheimer patients. Neurobiology of Aging, 2004, 25, 1299-1303.	3.1	162
216	Pedophilia: neuropsychological evidence encouraging a brain network perspective. Medical Hypotheses, 2004, 63, 528-531.	1.5	53

#	Article	IF	Citations
217	Huntingtonâ€™s Disease: Phenomenological Diversity of a Neuropsychiatric Condition That Challenges Traditional Concepts in Neurology and Psychiatry. American Journal of Psychiatry, 2004, 161, 28-34.	7.2	28
218	Effects of Long-Term Antipsychotic Treatment on NMDA Receptor Binding and Gene Expression of Subunits. Neurochemical Research, 2003, 28, 235-241.	3.3	51
219	Decreased gene expression of glial and neuronal glutamate transporters after chronic antipsychotic treatment in rat brain. Neuroscience Letters, 2003, 347, 81-84.	2.1	65
220	Effect of in vitro hemodilution with hydroxyethyl starch and dextran on the activity of plasma clotting factors. Critical Care Medicine, 2003, 31, 250-254.	0.9	27
221	Increased platelet phospholipase A2 activity in schizophrenia. Schizophrenia Research, 1995, 16, 1-6.	2.0	158
222	Gene expression of neuregulin-1 isoforms in different brain regions of elderly schizophrenia patients. World Journal of Biological Psychiatry, 0, , 1-8.	2.6	5